CStone Pharmaceuticals (CSPHF PINK) stock market data APIs
$0.5133
0(0%)
as of June 18, 2025
Try our APIs with
free plan!
CStone Pharmaceuticals Financial Data Overview
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally. The company offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, a RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. Its product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma. The company's products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for solid tumors; CS5001 for solid tumors and hematologic malignancies; and CS2013 and CS2015 for autoimmune diseases. The company was incorporated in 2015 and is headquartered in Suzhou, China.
Prev. Close
0.5133
Open
0.5133
High
0.5133
Low
0.5133
52 wk Range
0.114-0.518
Market Cap
443 M
Shares Outstanding
1 357 M
Revenue
407 M
EPS
-0.0519
Beta
0.14
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CStone Pharmaceuticals data using free add-ons & libraries
Get CStone Pharmaceuticals Fundamental Data
CStone Pharmaceuticals Fundamental data includes:
- Net Revenue: 407 M
- EBITDA: -92 787 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CStone Pharmaceuticals News
New
CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore
The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights. The deal enables Servier to potentially bring additio...
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metast...
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainland China. CStone to retain the rights to no...
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. This marks sugemalimab's third indicatio...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
